What Is Neomycin/Polymyxin B/Bacitracin? Definition and What Research Reports

Definition

Neomycin/polymyxin B/bacitracin is the naming convention for a fixed combination of three separately discovered antibacterial substances — neomycin sulfate, polymyxin B sulfate and bacitracin (or bacitracin zinc) — compounded together into a single topical preparation, most often an ointment for skin and in some formulations an ophthalmic ointment. The combination is commonly referred to in clinical shorthand as a "triple antibiotic" preparation, and it is listed in formularies and product labelling by the names of its three components rather than by a single chemical name, because it is a mixture rather than one molecule. In peptide literature the term is of interest mainly because two of its three ingredients are peptide-class natural products made by bacteria, so the name functions as a bridge between conventional antibacterial pharmacology and the chemistry of microbially produced peptides.

What Class of Molecule Is It?

The combination is not a single molecular class. It is better described as a three-component mixture spanning two structural families:

• Bacitracin — a cyclic polypeptide, or more precisely a family of closely related non-ribosomal peptides (bacitracin A being the principal component of commercial material) that includes a thiazoline ring and both L- and D-amino acid residues.
• Polymyxin B — a cyclic lipopeptide, built on a peptide ring rich in diaminobutyric acid residues with a fatty acyl chain attached, and supplied as a mixture of closely related congeners (chiefly B1 and B2).
• Neomycin — not a peptide. It is an aminoglycoside: an aminocyclitol core glycosidically linked to amino sugars, again supplied as a mixture of related components (neomycin B predominating).

Because bacitracin and polymyxin B are assembled by bacterial non-ribosomal peptide synthetase enzymes rather than by ribosomal translation, both contain residues and ring structures that do not appear in ordinary proteins. They are frequently used in textbooks as canonical examples of naturally occurring peptide antibiotics.

Where Each Component Comes From

How the Term Is Used in Peptide Research

The phrase appears in peptide-adjacent literature in three broad ways, all of them definitional rather than experimental.

1. As a named example of peptide natural products. When reviews discuss antimicrobial peptides of bacterial origin, bacitracin and polymyxin B are routinely cited as long-established examples, and the triple-combination name is the form in which most readers have encountered them.
2. As a comparator or background preparation in clinical and veterinary studies. Topical antibacterial combinations of this type are widely used, so they appear in wound-care and ocular-surface studies as the treatment being compared, the treatment given before enrolment, or the treatment whose bacterial susceptibility profile is being surveyed.
3. As an indexing and nomenclature term. Related product names — bacitracin/polymyxin B without neomycin, neomycin/polymyxin B/gramicidin, or combinations that add a corticosteroid — are distinct preparations, and the three-component name is used to distinguish them in databases and formulary lists.

None of these usages concerns the combination as a research peptide in the sense of a laboratory-only investigational compound. Neomycin/polymyxin B/bacitracin preparations are long-standing regulated pharmaceutical products, not research-use-only materials, and the peptide-glossary interest is structural.

What the Published Literature Reports

A 2016 Cochrane systematic review of topical antibiotics for preventing surgical site infection in wounds healing by primary intention reported that topical antibiotics applied to surgical wounds were associated with a lower risk of surgical site infection than no topical antibiotic and than topical antiseptics, with the reviewers grading the certainty of that evidence as low. The same review noted that the included trials covered a range of topical antibiotic preparations and that the evidence base was limited in size and quality. Reviews of this kind are the main place where combination topical antibacterials, including preparations containing neomycin, polymyxin B and bacitracin, are assessed collectively rather than individually.

On the ocular side, a 2020 survey of canine corneal disease reported the prevalence and antibiotic susceptibility of bacterial isolates cultured from dogs with ulcerative keratitis in the midwestern United States. Studies with this design exist because topical antibacterial choice for corneal ulcers depends on which organisms are actually recovered and what they are susceptible to, and the researchers in that work characterised those isolates rather than testing a treatment protocol.

A separate strand of the literature illustrates why antibacterial cover alone does not describe every corneal ulcer. A 2011 report described radial keratoneuritis as a presenting sign in Acanthamoeba keratitis, a protozoal infection that is outside the spectrum of antibacterial agents; the authors presented the finding as a clinical clue to the diagnosis. Together, these papers show the shape of the published evidence: microbiological surveys, systematic reviews of prevention outcomes, and case reports about diagnostic pitfalls.

Adverse Events: What Studies Report

The most frequently discussed tolerability issue for topical antibacterial combinations of this type is cutaneous hypersensitivity. In the 2016 Cochrane review, the reviewers reported that allergic contact dermatitis occurred in some participants in the included trials of topical antibiotics, and reported that adverse-event reporting across the included studies was inconsistent, which limited what could be concluded about harms. The veterinary susceptibility survey addressed which organisms were isolated and their in vitro susceptibility rather than patient-level adverse events, so it does not contribute harm data. This page is for educational purposes only and is not medical advice; consult a licensed physician or other qualified clinician about any medical or medication question.

Terminology Notes and Common Confusions

• The name describes a mixture, not a molecule. Statements about "neomycin/polymyxin B/bacitracin" cannot be assumed to apply to any single one of the three components.
• Formulations differ. Dermatologic ointments, ophthalmic ointments, and versions that omit one component or add a corticosteroid are separate preparations with separate labelling.
• Only two components are peptides. Neomycin is an aminoglycoside; describing the whole combination as a "peptide antibiotic" is imprecise.
• Human and veterinary literature are distinct. The canine keratitis survey reported isolates and susceptibility patterns in dogs, and such findings are not interchangeable with human ocular microbiology.
• Not every ulcer is bacterial. The Acanthamoeba keratitis report documented a presenting sign of a non-bacterial corneal infection, which is why diagnostic workup features heavily in the ocular literature.

Summary of the Entry

As a glossary term, neomycin/polymyxin B/bacitracin denotes a fixed three-component topical antibacterial preparation whose bacitracin and polymyxin B constituents are bacterially produced non-ribosomal peptides and whose neomycin constituent is an aminoglycoside. The published record cited here consists of a systematic review of topical antibiotic use in surgical wounds, a survey of bacterial isolates and susceptibility in canine corneal ulceration, and a case report on a diagnostic sign of Acanthamoeba keratitis. This entry summarises what those sources state and does not describe any protocol, regimen or application method.

References

• Topical antibiotics for preventing surgical site infection in wounds healing by primary intention (The Cochrane Database of Systematic Reviews, 2016)
• Prevalence and Antibiotic Susceptibility of Bacterial Isolates From Dogs With Ulcerative Keratitis in Midwestern United States (Frontiers in Veterinary Science, 2020)
• Radial keratoneuritis as a presenting sign in acanthamoeba keratitis (Middle East African Journal of Ophthalmology, 2011)